×
验证码:
换一张
Forgotten Password?
Stay signed in
Login With UMPASS
English
|
繁體
Login With UMPASS
Log In
ALL
ORCID
TI
AU
PY
SU
KW
TY
JN
DA
IN
PB
FP
ST
SM
Study Hall
Image search
Paste the image URL
Home
Faculties & Institutes
Scholars
Publications
Subjects
Statistics
News
Search in the results
Faculties & Institutes
Faculty of Heal... [13]
Institute of Chi... [7]
THE STATE KEY LA... [3]
Faculty of Scien... [1]
Authors
JOONG SUP SHIM [4]
LU JIAHONG [3]
LEUNG CHUNG HANG [2]
LUO QIAN [2]
LU JINJIAN [2]
WANG YITAO [1]
More...
Document Type
Journal article [21]
Date Issued
2023 [3]
2020 [3]
2019 [1]
2018 [3]
2017 [4]
2015 [2]
More...
Language
英語English [21]
Source Publication
Cancer Letters [15]
CANCER LETTERS [6]
Indexed By
SCIE [17]
Funding Organization
Funding Project
×
Knowledge Map
UM
Start a Submission
Submissions
Unclaimed
Claimed
Attach Fulltext
Bookmarks
Browse/Search Results:
1-10 of 21
Help
Selected(
0
)
Clear
Items/Page:
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
Sort:
Select
Issue Date Ascending
Issue Date Descending
Journal Impact Factor Ascending
Journal Impact Factor Descending
WOS Cited Times Ascending
WOS Cited Times Descending
Submit date Ascending
Submit date Descending
Title Ascending
Title Descending
Author Ascending
Author Descending
Combined inhibition of pyruvate dehydrogenase kinase 1 and lactate dehydrogenase a induces metabolic and signaling reprogramming and enhances lung adenocarcinoma cell killing
Journal article
Zhou, Yan, Guo, Yizhen, Ran, Maoxin, Shan, Wenying, Granchi, Carlotta, Giovannetti, Elisa, Minutolo, Filippo, Peters, Godefridus J., Tam, Kin Yip. Combined inhibition of pyruvate dehydrogenase kinase 1 and lactate dehydrogenase a induces metabolic and signaling reprogramming and enhances lung adenocarcinoma cell killing[J]. Cancer Letters, 2023, 577, 216425.
Authors:
Zhou, Yan
;
Guo, Yizhen
;
Ran, Maoxin
;
Shan, Wenying
;
Granchi, Carlotta
; et al.
Favorite
|
TC[WOS]:
9
TC[Scopus]:
7
IF:
9.1
/
8.3
|
Submit date:2023/12/04
Anticancer
Combination Treatment
Non-small Cell Lung Cancer
Warburg Effect
Lycorine promotes IDH1 acetylation to induce mitochondrial dynamics imbalance in colorectal cancer cells
Journal article
Fang-Fang Zhuo, Ling Li, Ting-Ting Liu, Xiao-Min Liang, Zhuo Yang, Yong-Zhe Zheng, Qian-Wei Luo, Jia-Hong Lu, Dan Liu, Ke-Wu Zeng, Peng-Fei Tu. Lycorine promotes IDH1 acetylation to induce mitochondrial dynamics imbalance in colorectal cancer cells[J]. Cancer Letters, 2023, 573, 216364.
Authors:
Fang-Fang Zhuo
;
Ling Li
;
Ting-Ting Liu
;
Xiao-Min Liang
;
Zhuo Yang
; et al.
Favorite
|
TC[WOS]:
7
TC[Scopus]:
9
IF:
9.1
/
8.3
|
Submit date:2023/09/22
Colorectal Cancer
Isocitrate Dehydrogenase (Idh)
Lycorine
Mitochondrial Dynamics
Oxidative Stress
Sirtuin 1
Reprogramming of TAMs via the STAT3/CD47-SIRPα axis promotes acquired resistance to EGFR-TKIs in lung cancer
Journal article
Lu, Jiaye, Li, Jingwei, Lin, Ziyou, Li, Huaxuan, Lou, Linlin, Ding, Wen, Ouyang, Shumin, Wu, Yonghui, Wen, Yuanzhen, Chen, Xiaobing, Yue, Peibin, Wang, Yuanxiang, Liu, Peiqing, Lu, Jinjian, Zhang, Jian, Feng, Weineng, Zhang, Xiaolei. Reprogramming of TAMs via the STAT3/CD47-SIRPα axis promotes acquired resistance to EGFR-TKIs in lung cancer[J]. Cancer Letters, 2023, 564, 216205.
Authors:
Lu, Jiaye
;
Li, Jingwei
;
Lin, Ziyou
;
Li, Huaxuan
;
Lou, Linlin
; et al.
Favorite
|
TC[WOS]:
25
TC[Scopus]:
25
IF:
9.1
/
8.3
|
Submit date:2023/07/20
Acquired Tki Resistance
Cd47
Lung Cancer
Stat3
Tams
Acetyltanshinone IIA is more potent than lapatinib in inhibiting cell growth and degrading HER2 protein in drug-resistant HER2-positive breast cancer cells
Journal article
Huang, Bin, Yip,Wai Kien, Wei, Na, Luo, Kathy Qian. Acetyltanshinone IIA is more potent than lapatinib in inhibiting cell growth and degrading HER2 protein in drug-resistant HER2-positive breast cancer cells[J]. Cancer Letters, 2020, 490, 1-11.
Authors:
Huang, Bin
;
Yip,Wai Kien
;
Wei, Na
;
Luo, Kathy Qian
Favorite
|
TC[WOS]:
8
TC[Scopus]:
8
IF:
9.1
/
8.3
|
Submit date:2021/03/02
Acetyltanshinone Iia
Drug Resistance
Her2 Degradation
Her2-positive Breast Cancer
Acetyltanshinone IIA is more potent than lapatinib in inhibiting cell growth and degrading HER2 protein in drug-resistant HER2-positive breast cancer cells
Journal article
Huang, B, Yip, WK, Na, W, Luo, KQ. Acetyltanshinone IIA is more potent than lapatinib in inhibiting cell growth and degrading HER2 protein in drug-resistant HER2-positive breast cancer cells[J]. Cancer Letters, 2020, 1-11.
Authors:
Huang, B
;
Yip, WK
;
Na, W
;
Luo, KQ
Favorite
|
IF:
9.1
/
8.3
|
Submit date:2022/08/26
Acetyltanshinone IIA
drug resistance
HER2-positive breast cancer
HER2 degradation
Artificial intelligence in cancer diagnosis and prognosis: Opportunities and challenges
Journal article
Huang, S, Yang, J, Fong, S., Zhao, Q.. Artificial intelligence in cancer diagnosis and prognosis: Opportunities and challenges[J]. Cancer Letters, 2020, 61-67.
Authors:
Huang, S
;
Yang, J
;
Fong, S.
;
Zhao, Q.
Favorite
|
IF:
9.1
/
8.3
|
Submit date:2023/08/25
Cancer diagnosis
Deep learning
Deep neural network
Machine learning
Prognosis prediction
Artificial intelligence in cancer diagnosis and prognosis: Opportunities and challenges
Journal article
Shigao Huang, Jie Yang, Simon Fong, Qi Zhao. Artificial intelligence in cancer diagnosis and prognosis: Opportunities and challenges[J]. Cancer Letters, 2019, 471, 61-71.
Authors:
Shigao Huang
;
Jie Yang
;
Simon Fong
;
Qi Zhao
Favorite
|
TC[WOS]:
279
TC[Scopus]:
355
IF:
9.1
/
8.3
|
Submit date:2021/03/04
Cancer Diagnosis
Prognosis Prediction
Deep Learning
Machine Learning
Deep Neural Network
PTEN deficiency confers colorectal cancer cell resistance to dual inhibitors of FLT3 and aurora kinase A
Journal article
Yifan Liu, Eun Ju Yang, Baoyuan Zhang, Zhengqiang Miao, Changjie Wu, Junfang Lyu, Kaeling Tan, Terence Chuen Wai Poon, Joong Sup Shim. PTEN deficiency confers colorectal cancer cell resistance to dual inhibitors of FLT3 and aurora kinase A[J]. CANCER LETTERS, 2018, 436, 28-37.
Authors: ; et al.
Favorite
|
TC[WOS]:
13
TC[Scopus]:
11
IF:
9.1
/
8.3
|
Submit date:2018/10/30
Akt
Kw2449
Synthetic Lethality
Aurka
Drug Combination
Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies
Journal article
Tang, Zheng-Hai, Lu, Jin-Jian. Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies[J]. CANCER LETTERS, 2018, 420, 242-246.
Authors:
Tang, Zheng-Hai
;
Lu, Jin-Jian
Favorite
|
TC[WOS]:
100
TC[Scopus]:
109
IF:
9.1
/
8.3
|
Submit date:2018/10/30
Osimertinib
Azd9291
Egfr Tki
Resistant Mechanisms
Therapeutic Strategies
Identification of a novel autophagic inhibitor cepharanthine to enhance the anti-cancer property of dacomitinib in non-small cell lung cancer
Journal article
Tang, Zheng-Hai, Cao, Wen-Xiang, Guo, Xia, Dai, Xiao-Yang, Lu, Jia-Hong, Chen, Xiuping, Zhu, Hong, Lu, Jin-Jian. Identification of a novel autophagic inhibitor cepharanthine to enhance the anti-cancer property of dacomitinib in non-small cell lung cancer[J]. CANCER LETTERS, 2018, 412, 1-9.
Authors:
Tang, Zheng-Hai
;
Cao, Wen-Xiang
;
Guo, Xia
;
Dai, Xiao-Yang
;
Lu, Jia-Hong
; et al.
Favorite
|
TC[WOS]:
36
TC[Scopus]:
38
IF:
9.1
/
8.3
|
Submit date:2018/10/30
Cepharanthine
Autophagy
Lysosome
Dacomitinib
Nsclc